We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for real-time alerts, custom portfolio, and market movers
| Share Name | Share Symbol | Market | Type |
|---|---|---|---|
| Pfizer Inc | NYSE:PFE | NYSE | Common Stock |
| Price Change | % Change | Share Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|
| 1.59 | 6.21% | 27.21 | 27.45 | 26.02 | 26.3295 | 97,521,966 | 00:59:15 |
From May 2022 to May 2024
By Dean Seal
Pfizer Inc. and partner BioNTech SE have asked the U.S. Food and Drug Administration to approve the use of its Omicron-specific Covid-19 vaccine booster shot for children.
The regulator granted this version of the vaccine an Emergency Use Authorization for use in people 12 or older on Aug. 31.
The companies said Monday that they have submitted an application for emergency use authorization of the 10-ug booster dose for children ages five to 11.
An application to approve the booster for children in Europe would be submitted to the European Medicines Agency in the next few days, the companies said.
Pfizer and BioNTech have launched a Phase 1/2/3 study to evaluate the safety of the shot for children as young as 6 months old, following the same regulatory guidance as trials of their original Covid-19 vaccine.
Write to Dean Seal at dean.seal@wsj.com
(END) Dow Jones Newswires
September 26, 2022 07:42 ET (11:42 GMT)
Copyright (c) 2022 Dow Jones & Company, Inc.
1 Year Pfizer Chart |
1 Month Pfizer Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
